compounded semaglutide being discontinued The FDA's Decision to Ban Compounds: What You Need to Know Makers of compounded Wegovy, Ozempic

Risk of Thyroid Cancer Among GLP1-RA Users

Description Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, allowing multi-use vial access over an extended period

This triple-agonist approach explains why clinical trial participants achieved average weight loss of 24.2% at the 12mg dose over 48 weeks

Higher risk factors were a history of type 2 diabetes, tobacco use and advanced chronic kidney disease ( stage 3)